The global lenalidomide drug market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market is the increasing prevalence of myeloma cancer. According to American Cancer’s Society, in 2021, around 34,920 cases have been diagnosed with multiple myeloma, which is leading to increasing demand for lenalidomide drugs. 

This drug is used for the treatment of multiple myeloma, it is equivalent to thalidomide, however, have fewer side effects such as constipation, sedation, and neuropathy as compared to thalidomide. This drug is used to treat anaemia in patients who are suffering from some kind of myeloma. This drug is also used to treat another disease referred to as mantle cell lymphoma. Even though the treatment for myeloma cancer has advanced rapidly over the years, this disease is still incurable. Myeloma cancer starts in the bone marrow, where the disease causes the antibody-producing cells to transform into cancerous myeloma cells, due to which the formation of abnormal antibodies takes place in the body. The lenalidomide is used in another treatment apart from multiple myeloma, such as myelodysplastic syndrome, and others. 

Lenalidomide is primarily used for the management of the myelodysplastic syndrome. In September 2021, Dr Reddy’s Laboratories launched the generic version of Lenalidomide known as Reddy- Lenalidomide in Canada. This drug will be used to treat patients who are diagnosed with transfusion-dependent anaemia due to the risk of myelodysplastic syndrome. There have been numerous drugs developed in recent years to treat multiple myeloma, due to which the total survival rate of patients suffering from multiple myeloma has increased as compared to previous years, while toxicity is one of the side effects which is restraining the growth of the lenalidomide market. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Type

o By Application

• Regions Covered 

o North America

o Europe

o Asia-Pacific

o Rest of the Word

• Competitive Landscape - Celgene and SL Pharma

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Lenalidomide Drug Market 

o By Type 

• 5 mg capsule
• 10 mg capsule
• 15 mg capsule
• 25 mg capsule

o By Application 

• Multiple Myeloma
• Myelodysplastic syndrome
• Others